Particularly noteworthy is that in patients with both type 2 diabetes and MASLD, after 24 weeks of treatment with a 10 mg dose of efinopegdutide, liver fat content reduced by 72.7%, a result that is superior to the 42.3% reduction achieved with a 1 mg dose of semaglutide, despite a similar overall weight loss being observed with the two interventions
Key active ingredients include Sodium
Your BPC-157 protocol is prepared by our licensed 503A compounding pharmacy partner
In type 2 diabetes, much of the evidence comes from post hoc analyses of trials that primarily examine the effects of single drugs compared with placebo
Common causes include water retention (especially after dose increases or during hormonal fluctuations), muscle gain offsetting fat loss (particularly in people who are exercising consistently), metabolic adaptation, and changes in dietary habits that may have gradually increased caloric intake
Find out what insurance plans cover weight loss medication in 2026